過敏診斷市場機會、成長動力、產業趨勢分析與 2025 - 2034 年預測

2024 年全球過敏診斷市場價值為 66 億美元，預計 2025 年至 2034 年期間的複合年成長率為 10.9%，這主要得益於氣喘、鼻炎和食物過敏等過敏症的盛行率不斷上升。隨著生活方式的改變、污染水平的上升和環境觸發因素的增多，對準確、有效的過敏測試解決方案的需求從未如此高漲。多重檢測和免疫測定等診斷技術的快速進步正在透過提高精確度、效率和患者舒適度徹底改變過敏測試。這些創新使醫療保健提供者能夠以更快的速度和更高的準確性檢測更廣泛的過敏原，確保及時有效地管理患者。

過敏性疾病影響全球數百萬人，其日益加重的經濟負擔也推動了市場的擴張。醫療保健提供者和研究機構正在積極投資先進的診斷工具，以改善早期檢測和個人化治療方法。人們對早期診斷益處的認知不斷提高，加上醫療保健支出的不斷增加，進一步推動了對複雜過敏測試解決方案的需求。此外，實驗室擴大採用自動化技術，簡化了過敏診斷流程，減少了人為錯誤，提高了測試的可重複性，使過敏測試更加方便和可靠。

過敏診斷市場依產品和服務分為消耗品、儀器和服務。其中，預計消耗品將佔據市場主導地位，年複合成長率為 10.8%，到 2034 年將達到 102 億美元。過敏性疾病的盛行率不斷上升，加上其高昂的醫療費用，推動了對試劑和檢測試劑盒等消耗品的需求。由於環境變化導致過敏現象越來越普遍，對能夠準確識別過敏原的先進診斷解決方案的需求也日益增加。

就測試類型而言，市場分為體內測試和體外測試。預計體內測試部分將為市場擴張做出重大貢獻，年複合成長率為 10.6%，到 ​​2034 年將超過 96 億美元。皮膚點刺試驗和皮內測試對於診斷各種過敏症仍然至關重要，因為它們可以提供快速、可靠的結果。它們價格實惠、準確且易於在臨床環境中使用，使其成為醫療保健專業人士的首選。這些測試對於檢測環境因素、食物和昆蟲毒液引起的過敏特別有效，進一步推動了它們的應用。

美國過敏診斷市值在 2024 年將達到 23 億美元，預計在 2025 年至 2034 年期間的複合年成長率為 10.2%。該國過敏症發病率的不斷上升、醫療服務提供者和患者意識的不斷增強以及向個人化治療方法的日益轉變是推動市場成長的關鍵因素。對精確診斷工具的需求不斷成長，加上強大的醫療保健基礎設施和技術進步，進一步增強了市場前景。隨著過敏相關疾病的持續增加，美國市場有望大幅擴張，為診斷製造商和醫療保健提供者提供有利可圖的機會。

目錄

第 1 章：方法論與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業衝擊力
  • 成長動力
    • 過敏性疾病盛行率不斷上升，經濟負擔沉重
    • 污染加劇，呼吸道疾病增多
    • 過敏診斷公司融資增加
    • 兒童過敏意識
    • 新產品的技術進步
  • 產業陷阱與挑戰
    • 過敏診斷儀價格昂貴
    • 對過敏性疾病的認知有限
• 成長潛力分析
• 監管格局
• 技術格局
• 差距分析
• 波特的分析
• PESTEL 分析
• 未來市場趨勢
• 價值鏈分析
• 過敏診斷與管理的創新
• 食物過敏診斷的未來
• 人工智慧增強過敏診斷

第4章：競爭格局

• 介紹
• 公司矩陣分析
• 公司市佔率分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 策略儀表板

第 5 章：市場估計與預測：按產品和服務，2021 年至 2034 年

• 主要趨勢
• 耗材
• 儀器
• 服務

第6章：市場估計與預測：按測試類型，2021 年至 2034 年

• 主要趨勢
• 體內
  • 皮膚點刺試驗
  • 皮內皮膚試驗
  • 其他體內測試類型
• 體外

第 7 章：市場估計與預測：按過敏原，2021 — 2034 年

• 主要趨勢
• 吸入過敏原
• 食物過敏原
• 藥物過敏原
• 其他過敏原

第 8 章：市場估計與預測：依最終用途，2021 年至 2034 年

• 主要趨勢
• 診斷實驗室
• 醫院實驗室
• 其他最終用戶

第9章：市場估計與預測：按地區，2021 年至 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第10章：公司簡介

• BIOMERIEUX
• danaher
• eurofins
• EUROIMMUN
• HITACHI
• HOB
• hycor
• LINCOLN Diagnostics INC.
• MINARIS Medical
• NEOGEN CORPORATION
• Omega DIAGNOSTICS GROUP PLC
• r-biopharm
• SIEMENS Healthcare Diagnostics
• STALLERGENES
• Thermo Fisher SCIENTIFIC

The Global Allergy Diagnostics Market was valued at USD 6.6 billion in 2024 and is projected to expand at a CAGR of 10.9% between 2025 and 2034, driven by an increasing prevalence of allergic conditions such as asthma, rhinitis, and food allergies. With changing lifestyles, rising pollution levels, and growing environmental triggers, the demand for accurate and efficient allergy testing solutions has never been higher. The rapid advancements in diagnostic technologies, including multiplex assays and immunoassays, are revolutionizing allergy testing by improving precision, efficiency, and patient comfort. These innovations allow healthcare providers to detect a broader range of allergens with enhanced speed and accuracy, ensuring timely and effective patient management.

The market expansion is also fueled by the increasing economic burden of allergic diseases, which affect millions of individuals worldwide. Healthcare providers and research institutions are actively investing in advanced diagnostic tools to improve early detection and personalized treatment approaches. The growing awareness about the benefits of early diagnosis, coupled with rising healthcare expenditures, is further driving demand for sophisticated allergy testing solutions. In addition, the increasing adoption of automation in laboratories is streamlining allergy diagnostics, reducing human error, and enhancing test reproducibility, making allergy testing more accessible and reliable.

The allergy diagnostics market is classified by product and service into consumables, instruments, and services. Among these, consumables are expected to dominate the market, growing at a CAGR of 10.8% and reaching USD 10.2 billion by 2034. The rising prevalence of allergic diseases, combined with their substantial healthcare costs, is fueling demand for consumables, including reagents and test kits. With allergies becoming more widespread due to environmental changes, the need for advanced diagnostic solutions that offer accurate allergen identification is increasing.

In terms of test type, the market is categorized into in vivo and in vitro tests. The in vivo segment is projected to contribute significantly to market expansion, growing at a CAGR of 10.6% and surpassing USD 9.6 billion by 2034. Skin prick tests and intradermal tests remain essential for diagnosing various allergies, as they provide quick, reliable results. Their affordability, accuracy, and ease of use in clinical settings make them a preferred choice among healthcare professionals. These tests are particularly effective in detecting allergies caused by environmental factors, food, and insect venom, further driving their adoption.

The U.S. allergy diagnostics market, valued at USD 2.3 billion in 2024, is expected to grow at a CAGR of 10.2% between 2025 and 2034. The country's increasing rates of allergic conditions, heightened awareness among healthcare providers and patients, and the growing shift toward personalized treatment approaches are key factors propelling market growth. The rising need for accurate diagnostic tools, combined with strong healthcare infrastructure and technological advancements, is further strengthening the market outlook. As allergy-related disorders continue to rise, the U.S. market is poised for substantial expansion, providing lucrative opportunities for diagnostic manufacturers and healthcare providers alike.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence and high economic burden of allergic diseases
    • 3.2.1.2 Growing pollution levels coupled with rise in respiratory disorders
    • 3.2.1.3 Rise in funding for allergy diagnostics companies
    • 3.2.1.4 Pediatric allergy awareness
    • 3.2.1.5 Technological advancements in new products
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of allergy diagnostic instrument
    • 3.2.2.2 Limited awareness related to allergic diseases
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technology landscape
• 3.6 Gap analysis
• 3.7 Porter's analysis
• 3.8 PESTEL analysis
• 3.9 Future market trends
• 3.10 Value chain analysis
• 3.11 Innovations in allergy diagnostics and management
• 3.12 The future of food allergy diagnosis
• 3.13 AI-enhanced allergy diagnostics

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product and Service, 2021 — 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Consumables
• 5.3 Instruments
• 5.4 Services

Chapter 6 Market Estimates and Forecast, By Test Type, 2021 — 2034 ($ Mn)

• 6.1 Key trends
• 6.2 In Vivo
  • 6.2.1 Skin prick tests
  • 6.2.2 Intradermal skin test
  • 6.2.3 Other in vivo test types
• 6.3 In Vitro

Chapter 7 Market Estimates and Forecast, By Allergen, 2021 — 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Inhaled allergens
• 7.3 Food allergens
• 7.4 Drug allergens
• 7.5 Other allergens

Chapter 8 Market Estimates and Forecast, By End Use, 2021 — 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Diagnostic laboratories
• 8.3 Hospital-based laboratories
• 8.4 Other end users

Chapter 9 Market Estimates and Forecast, By Region, 2021 — 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 BIOMERIEUX
• 10.2 danaher
• 10.3 eurofins
• 10.4 EUROIMMUN
• 10.5 HITACHI
• 10.6 HOB
• 10.7 hycor
• 10.8 LINCOLN Diagnostics INC.
• 10.9 MINARIS Medical
• 10.10 NEOGEN CORPORATION
• 10.11 Omega DIAGNOSTICS GROUP PLC
• 10.12 r-biopharm
• 10.13 SIEMENS Healthcare Diagnostics
• 10.14 STALLERGENES
• 10.15 Thermo Fisher SCIENTIFIC